Product Description
Ammoxetine is a novel selective serotonin and norepinephrine reuptake inhibitor. Preclinical studies have indicated the potential utility of ammoxetine for therapy in major depressive disorder. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/33482315/)
Mechanisms of Action: SNR Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: CSPC
Company Location:
Company Founding Year: 1997
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: China
Active Clinical Trial Count: 3
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Depressive Disorder, Major
Phase 2: Depressive Disorder
Phase 1: Healthy Volunteers
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
CTR20230246 |
CTR20230246 | P2 |
Completed |
Depressive Disorder |
2024-07-19 |
2025-04-29 |
Patient Enrollment|Primary Completion Date|Study Completion Date|Treatments|Trial Status |
|
NCT06827431 |
HA1406-007 | P3 |
Not yet recruiting |
Depressive Disorder, Major |
2026-06-30 |
21% |
2025-02-15 |
Primary Endpoints|Treatments |
NCT07508462 |
HA1406-006 | P1 |
Completed |
Healthy Volunteers |
2024-06-17 |
2026-04-03 |
Primary Endpoints |
Recent News Events
Date |
Type |
Title |
|---|